$TWST

Cho Dennis sold $1.3M of TWST

Cho Dennis (See Remarks) sold 14,205 shares of Twist Bioscience Corp (TWST) at $89.75 ($1.27M total) on 2026-06-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cho Dennis
Published Jun 26, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 6:57 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$TWST
Neutral
high confidence
Mentioned
$TWST
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

The only new information is the specific sale size, price, and post-transaction holdings under a 10b5-1 plan; it does not include any new company performance, guidance, or regulatory developments.

02

Market read

Traders may note the insider selling activity, but the 10b5-1 structure and lack of fundamental updates make it low-conviction for directional trading.

03

What to watch

The article does not state whether other insiders sold/bought around the same window, nor does it provide context on total planned volume or remaining plan size.

Relevance 5/10Novelty 3/10Timing: filed June 26, covering a June 24 sale

Background

The article is a SEC Form 4 insider transaction disclosure for Twist Bioscience, reported via SEC EDGAR.

Company-level read

Ticker impact

$TWSTNeutralHigh confidence
Context

Twist Bioscience insider Dennis Cho filed a Form 4 open-market sale of 14,205 shares at $89.75 on June 24 under a 10b5-1 plan.

Expected impact

Likely minimal price impact; any effect is short-lived and sentiment-driven rather than fundamental.

Evidence & confidence

The filing is an open-market sale under a pre-arranged 10b5-1 plan, with no accompanying operational or guidance change disclosed in the text.

Market effects

No clear sector read-through from a single routine insider sale disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is on a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations, so traders may discount it.

Key entities

  • Twist Bioscience Corp

    Subject of the Form 4 insider transaction disclosure.

  • Dennis Cho

    Officer who executed the open-market sale under a pre-arranged 10b5-1 plan.

Related articles

$TWSTMedAI 8/10

Twist Announces Pricing Of $300 Mln Underwritten Upsized Public Offering

Twist Bioscience (TWST) priced an underwritten upsized public offering of 3.12 million shares at $96.00 each, raising about $300 million in gross proceeds. Underwriters received a 30-day option for up to an additional $37.5 million. Proceeds will fund R&D, manufacturing expansion, working capital and general purposes. Closing is expected Aug. 6, 2026.

$TWSTMed

Twist Bioscience Q3 Earnings Call Highlights

Twist Bioscience (NASDAQ:TWST) reported Q3 revenue of about $77.3M in the Americas (+30% YoY), $33.6M in EMEA (+9%), and $7.5M in APAC (+26%). Global supply partner revenue was $12.9M. Gross margin was 52.8%. It raised FY2026 revenue guidance to $456M-$457M and forecast Q4 revenue of $123M-$124M.

$TWSTMed

Why is Twist Bioscience stock sliding today?

Twist Bioscience shares (TWST) fell 4.2% in pre-open after its fiscal Q3 results missed EPS expectations. The company reported an EPS loss of $0.56 versus $0.48 expected, while revenue was $118.4M, above the $114.54M estimate. The miss follows similar EPS shortfalls in prior quarters, with mixed analyst actions noted.

$TWSTHigh

Twist Bioscience Corp (TWST): Results of Operations and Financial Condition

Twist Bioscience Corp (TWST) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 twst-2026630xex991.htm EX-99.1 Document Exhibit 99.1 Twist Bioscience Reports Fiscal Third Quarter 2026 Financial Results — Record revenue of $118.4 million in 3QFY26 ; Increase of more than 23% over $96.1 million in 3QFY25; 14th consecutive quarter of sequential growth

$AMDMedAI 8/10

Cathie Wood Pours $8. 5M Into Cerebras Amid Buzz Around AI Chip Upstart, Wont Stop Dumping AMD - Advanced

According to Benzinga, Cathie Wood’s Ark made a $10.8M purchase of Cerebras shares (42,126) on Friday, while also selling 16,998 shares of Teradyne and buying 2,451 shares of Twist Bioscience via ARKK. Separately, the report notes AMD is ramping Vera Rubin production, but U.S.-China policy and China’s share of net sales remain key factors for investors.